---
document_datetime: 2023-09-21 22:01:23
document_pages: 24
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/pergoveris-epar-procedural-steps-taken-authorisation_en.pdf
document_name: pergoveris-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 12.8279103
conversion_datetime: 2025-12-18 09:54:21.756783
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Pergoveris

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                               | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0085              | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol | 26/05/2023                          |                                             | SmPC                             |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IB/0084   | B.I.b.1.z - Change in the specification parameters limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 09/05/2023   | n/a   | and/or   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|----------|
| IA/0083/G | This was an application for a group of variations. B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of | 03/03/2023   | n/a   |          |

<div style=\"page-break-after: always\"></div>

|           | in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method                                                                                                                                       |            |            |    | B.I.b.1.b - Change   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|----------------------|
| IB/0082   | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                                                                                            | 23/11/2022 | n/a        |    |                      |
| WS/2275/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.I.e.2 - Introduction of a post approval change management protocol related to the AS | 27/10/2022 | n/a        |    |                      |
| N/0081    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                | 17/08/2022 | 14/10/2022 | PL |                      |

<div style=\"page-break-after: always\"></div>

| IB/0080            | B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 11/07/2022   | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/1464/ 202110 | Periodic Safety Update EU Single assessment - follitropin alfa / lutropin alfa                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 10/06/2022   | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IA/0079            | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 25/05/2022   | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| II/0075            | Update of sections 4.1, 4.2, 4.4, 5.1, 5.2, 6.6 of the SmPC in order to revise the definition of severe LH and FSH deficiency and to clarify the treatment target and the pharmacokinetic and pharmacodynamic properties of the two gonadotropins included in the medicinal product, as well as disposal precautions, based on current medical guidelines, clinical practice and literature; the Package Leaflet and Labelling are updated accordingly. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.2 and to align with the guideline on the Excipients in the labelling and package leaflet of the medicinal products for human use. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 14/10/2021   | 14/10/2022 | SmPC, Annex II, Labelling and PL | Provision of context and alignment regarding the definition of severe LH and FSH deficiency based on current medical guidelines and standards of clinical care in section 4.1. of the SmPC, as well as description of the physiologic action of Pergoveris and its use in relevant clinical settings associated with Medically Assisted Reproduction in section 4.2 of the SmPC. Clarification and reorganisation of information in section 5.1 of the SmPC. For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

| IA/0076/G   | This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method   | 16/07/2021   | n/a   |               |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|---------------|
| IB/0073     | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 26/05/2021   | n/a   |               |
| II/0072     | B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a                                                                                                                                                                                                                                                                                                                                                       | 29/04/2021   | n/a   | biological AS |
| IA/0074     | B.II.f.1.e - Stability of FP - Change to an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 13/04/2021   | n/a   |               |

<div style=\"page-break-after: always\"></div>

| II/0068   | B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol                                                                                                                                                                                                                                                                   | 10/09/2020   | n/a   |                |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|----------------|
| II/0071   | B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method                                                                                                                                                                                                                                                                     | 04/09/2020   | n/a   | Not applicable |
| II/0069   | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                              | 23/07/2020   | n/a   |                |
| IB/0070/G | This was an application for a group of variations. B.II.b.1.f - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/ immunological medicinal products B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - | 24/06/2020   | n/a   |                |

<div style=\"page-break-after: always\"></div>

|           | control/testing takes place B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size                                                                                                                                                                                                                                   |            |     |           |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------|
| WS/1799/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.4.d - Change to in-process tests or limits applied during the manufacture of the AS - Widening of the approved in-process test limits, which may have a significant effect on the overall quality of the AS B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a | 18/06/2020 | n/a | new or an |
| II/0066   | Submission of an updated RMP version 5.3 (updated to version 6.0) in order to adapt to the RMP template as per Good Pharmacovigilance Practice (GVP) Module V, rev 2, with consequential removal of important identified risks and important potential risks.                                                                                                                                                                                                                                                                                                 | 12/03/2020 | n/a |           |

<div style=\"page-break-after: always\"></div>

|           | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required                                                                     |            |     |                        |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------|
| IB/0064/G | This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure | 13/11/2019 | n/a | (including replacement |
| IA/0065   | B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation                                                                                                                                                                                                                                                        | 30/10/2019 | n/a |                        |
| IB/0063   | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                       | 20/08/2019 | n/a |                        |
| IB/0062   | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale time data)                                                                                                                                                                                                                                             | 08/07/2019 | n/a | (supported by real     |

<div style=\"page-break-after: always\"></div>

| PSUSA/1464/ 201810   | Periodic Safety Update EU Single assessment - follitropin alfa / lutropin alfa                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 14/06/2019   | n/a        |                        | PRAC Recommendation - maintenance   |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-------------------------------------|
| IA/0060              | B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 12/12/2018   | n/a        |                        |                                     |
| T/0059               | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 30/07/2018   | 20/08/2018 | SmPC, Labelling and PL |                                     |
| IB/0058              | B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 28/06/2018   | n/a        |                        |                                     |
| II/0055              | Update of the Pergoveris Risk Management Plan to version 5.2 in order to: · Align the RMP template with Good Pharmacovigilance Practice (GVP) Module V, revision 1. · Add the reference to Pergoveris solution for injection in pre-filled pen (300IU/150IU, 450IU/225IU and 900IU/450IU) following the approval in the European Union (EU) on the 8th of May 2017. Additionally, minor updates have been introduced to the safety specification sections based on the data reviewed until the most recent data lock point. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing | 14/06/2018   | n/a        |                        |                                     |

<div style=\"page-break-after: always\"></div>

|           | authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required                                                                                                                                                                                                                                                      |            |     |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0057   | B.II.e.4.c - Change in shape or dimensions of the container or closure (immediate packaging) - Sterile medicinal products                                                                                                                                                                                                                                                                                                                                | 08/05/2018 | n/a |
| IB/0056   | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                                                                                                                               | 11/04/2018 | n/a |
| II/0054/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes | 22/02/2018 | n/a |
| IB/0053/G | This was an application for a group of variations. B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a                                                                                                                                                                                                                   | 21/09/2017 | n/a |

<div style=\"page-break-after: always\"></div>

|           | new or an already approved manufacturer B.III.1.b.4 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Deletion of certificates (in case multiple certificates exist per material)                                                                                                                                                                                                                                                                     |            |            |                                  |                       |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------|
| II/0052/G | This was an application for a group of variations. B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting | 14/09/2017 | n/a        |                                  | material/intermediate |
| IB/0051   | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                                                           | 27/07/2017 | n/a        |                                  |                       |
| R/0050    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 23/02/2017 | 08/05/2017 | Annex II, Labelling and PL       |                       |
| X/0047    | Extension application to introduce a new pharmaceutical form (solution for injection) associated with 3 new presentations of (300 IU, 150 IU)/ 0.48 ml, (450 IU, 225 IU)/ 0.72 ml and (900 IU,                                                                                                                                                                                                                                                                                             | 23/02/2017 | 08/05/2017 | SmPC, Annex II, Labelling and PL |                       |

<div style=\"page-break-after: always\"></div>

|                    | 450 IU)/ 1.44 ml. Annex I_2.(d) Change or addition of a new pharmaceutical form                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |     |                                   |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| IB/0049            | B.I.a.4.f - Change to in-process tests or limits applied during the manufacture of the AS - Addition or replacement of an in-process test as a result of a safety or quality issue                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 02/09/2016 | n/a |                                   |
| IA/0048/G          | This was an application for a group of variations. B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method | 01/09/2016 | n/a |                                   |
| PSUSA/1464/ 201510 | Periodic Safety Update EU Single assessment - follitropin alfa / lutropin alfa                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 09/06/2016 | n/a | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| IB/0046   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                     | 23/03/2016   | n/a   |                                        |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|----------------------------------------|
| IA/0045   | B.II.e.3.b - Change in test procedure for the immediate packaging of the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                                                                 | 25/02/2016   | n/a   |                                        |
| WS/0655   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Change in test procedure for AS and FP B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | 20/11/2014   | n/a   | Change in test procedure for AS and FP |
| IG/0500   | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                   | 17/11/2014   | n/a   |                                        |
| IA/0042   | B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information                                                                                                                                                                                                                    | 21/10/2014   | n/a   |                                        |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| WS/0579/G   | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other variation B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other variation B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other variation B.III.2.z - Change to comply with Ph. Eur. or with a   | 24/07/2014   | n/a   |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|

<div style=\"page-break-after: always\"></div>

|           | B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation   |            |     | variation   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|
| IG/0461   | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                                                                                                               | 22/07/2014 | n/a |             |
| WS/0506   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Change to the manufacturing process of the active substance. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                   | 20/03/2014 | n/a |             |
| IA/0038/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 24/01/2014 | n/a |             |

<div style=\"page-break-after: always\"></div>

|         | B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier                                                                                                                                    |            |            |                                  |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|
| IB/0037 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                            | 20/01/2014 | 03/02/2015 | SmPC, Annex II, Labelling and PL |
| IG/0395 | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                              | 20/12/2013 | n/a        |                                  |
| WS/0457 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Change to the control of the active substance. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | 18/12/2013 | n/a        |                                  |
| IB/0034 | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other                                                                                                                                                                                                                                                                                                             | 31/10/2013 | n/a        |                                  |

<div style=\"page-break-after: always\"></div>

|           | to a test procedure (including replacement addition) for the AS or a starting                                                                                                                                                                                                                                 |            |            |    | changes or material/intermediate   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|------------------------------------|
| IB/0033/G | This was an application for a group of variations. B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits | 18/10/2013 | n/a        |    |                                    |
| IG/0361   | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                           | 04/10/2013 | n/a        |    |                                    |
| N/0029    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                              | 02/10/2013 | 03/02/2015 | PL |                                    |
| IG/0358   | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                           | 25/09/2013 | n/a        |    |                                    |
| WS/0380   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Change to the control of the active substance B.I.a.4.b - Change to in-process tests or limits manufacture of the AS - Addition                                 | 30/05/2013 | n/a        |    | applied during the                 |

<div style=\"page-break-after: always\"></div>

|         | of a new in-process test and limits                                                                                                                                                                                                                                                                                                                                                                                     |            |            |    |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|
| N/0027  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                        | 12/12/2012 | 03/02/2015 | PL |
| IB/0025 | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                                                                                                                  | 05/12/2012 | n/a        |    |
| IG/0224 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                          | 11/10/2012 | n/a        |    |
| WS/0294 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Change to the control of the drug substance and drug product B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | 20/09/2012 | n/a        |    |
| WS/0275 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Change to the control of the finished product                                                                                                                                                                                                                             | 19/07/2012 | n/a        |    |

<div style=\"page-break-after: always\"></div>

|         | B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation                                                                                                                                                             |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0021  | Renewal of the marketing authorisation.                                                                                                                                                                                                                                 | 15/03/2012 | 22/05/2012 | SmPC, Annex II, Labelling and PL | Based upon the data that have become available since the granting of the initial Marketing Authorisation, the CHMP considers that the benefit-risk balance of Pergoveris remains positive, but considers that its safety profile has to be closely monitored since there are grounds for suspecting significant off-label use of Pergoveris in Assisted Reproductive Technology (ART) for women who do not have severe LH and FSH deficiency, and a number of issues are still required monitoring in the risk management plan, including potential side effects with long latency. Therefore, based upon the safety profile of Pergoveris, which requires submission of three yearly PSURs, the CHMP concluded that the MAH should submit one additional renewal application in 5 years time. |
| IB/0022 | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                            | 06/01/2012 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| WS/0174 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Change to the manufacturing process of lutropin alfa active substance B.I.a.2.c - Changes in the manufacturing process of | 20/10/2011 | 20/10/2011 |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|           | AS - The change refers to a [-] substance in the of a biological/immunological medicinal and is not related to a protocol                                                                                                                                                                                                                                                                                                            |            |            |                 | the manufacture product   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|---------------------------|
| WS/0148   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. New TSE certificate for a raw material used in the manufacture of the active substance. B.III.1.b.2 - Submission of a new or updated Ph. Eur. TSE Certificate of suitability - New certificate for a starting material/reagent/intermediate/or excipient already approved manufacturer | 21/07/2011 | 21/07/2011 |                 | from a new or an          |
| IG/0087   | B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State                                                                                                                                                                                                                | 18/07/2011 | n/a        |                 |                           |
| IG/0076/G | This was an application for a group of variations. C.I.9.a - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the QPPV C.I.9.b - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the contact details of the QPPV Changes to an existing pharmacovigilance                                                                                                   | 01/07/2011 | n/a        | Annex II and PL | C.I.9.h -                 |

<div style=\"page-break-after: always\"></div>

|           | system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system                                                                                                                                                                                                               |            |            |                               |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------------------------|
| IB/0015/G | This was an application for a group of variations. B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with | 06/01/2011 | n/a        | its corresponding test method |
| II/0014   | Change to the purification process of the active substance B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological medicinal product and is not related to a protocol                                                                                  | 16/12/2010 | 04/01/2011 |                               |
| WS/0016   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Change of reference standard B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other (including replacement                                                   | 24/06/2010 | 24/06/2010 | changes to a test procedure   |

<div style=\"page-break-after: always\"></div>

|         | or addition) for the AS or a starting material/intermediate                                                                                                      |            |            |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0013 | Update of the Detailed Description of the Pharmacovigilance system (DDPS). In addtion mistakes in the PI have been corrected. Update of DDPS (Pharmacovigilance) | 22/04/2010 | 10/06/2010 | Annex II and PL | With this variation the MAH submitted a new version of the DDPS (core version 9.0) in accordance with the current Pharmacovigilance guideline. After assessing the documentation the CHMP concluded that the submitted DDPS contained all required elements. Consequently, Annex II has been updated with the new version number of the agreed DDPS. In addition the MAH took the opportunity to amend the following: - Correct mistakes in the 'Possible side effects' section of the Patient Leaflet which applies to all EU languages - Update the list of representatives in the Patient Leaflet (Bulgaria, Denmark, Germany, Estonia, Latvia, Lithuania, Sweden) which applies to all EU languages - Correct grammatical/linguistic errors in some national translations of the Product Information |
| II/0012 | Change to the shelf life of the drug substance Change(s) to shelf-life or storage conditions                                                                     | 21/01/2010 | 02/02/2010 |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| N/0011  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                 | 21/01/2010 | n/a        | PL              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IA/0010 | IA_04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.)                                                               | 09/07/2009 | n/a        | Annex II        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

| IA/0009   | IA_01_Change in the name and/or address of the marketing authorisation holder                                                                                                        | 09/07/2009   | n/a        | SmPC, Labelling and PL   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|--------------------------|
| II/0008   | Change of reference standard Change(s) to the test method(s) and/or specifications for the active substance                                                                          | 25/06/2009   | 25/06/2009 |                          |
| N/0007    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                     | 26/05/2009   | n/a        | Labelling and PL         |
| IA/0006   | IA_04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.) IA_05_Change in the name and/or address of a manufacturer of the finished product | 24/03/2009   | n/a        | Annex II                 |
| IA/0005   | IA_05_Change in the name and/or address of a manufacturer of the finished product                                                                                                    | 14/11/2008   | n/a        | Annex II and PL          |
| IA/0004   | IA_04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.) IA_05_Change in the name and/or address of a manufacturer of the finished product | 14/11/2008   | n/a        |                          |
| II/0003   | Change(s) to the manufacturing process for the active substance                                                                                                                      | 30/05/2008   | 26/06/2008 |                          |
| II/0002   | Change(s) to the manufacturing process for the active substance                                                                                                                      | 21/02/2008   | 04/04/2008 | Annex II                 |

<div style=\"page-break-after: always\"></div>

| to the manufacturing process for the substance   | 21/02/2008   | 26/02/2008   | II/0001 Change(s) active   |
|--------------------------------------------------|--------------|--------------|----------------------------|